We examine how real-world evidence strategies help address uncertainties in rare disease treatments ...
Read moreAchieving HTA approval for orphan drugs requires strategic planning, early engagement, strong eviden...
Read moreThe recent appraisal by the National Institute for Health and Care Excellence (NICE) for Iptacopan, ...
Read moreWe're thrilled to announce our participation at World Orphan Drug Congress Europe 2024 in Barcelona ...
Read moreNICE recommends gene therapy for severe beta-thalassaemia, offering hope for improved quality of lif...
Read moreThe World Evidence, Pricing, and Access (EPA) Congress stands as Europe’s premier event in mar...
Read moreWe're thrilled to announce our participation at ISPOR Europe 2023 in Copenhagen this November. We'll...
Read moreWe've updated our 2019 analysis which compares the annual and lifetime treatment costs of the 10 mos...
Read moreWebinar: Our experts discuss Orphan medicine market access in Europe including the impact of EU HTA ...
Read moreThis article explores the new EU pharmaceutical package and criteria of high unmet medical need (HUM...
Read more